云南白药(000538) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 12,750,996,996.14, representing an increase of 11.49% compared to the same period last year[5] - Net profit attributable to shareholders was CNY 1,517,988,356.56, a significant increase of 66.01% year-on-year[5] - Basic earnings per share increased by 19.72% to CNY 0.85 from CNY 0.71 in the same period last year[5] - Total operating revenue for Q1 2023 reached CNY 10,512,750,996.14, an increase of 11.5% compared to CNY 9,429,539,929.02 in Q1 2022[19] - Net profit for Q1 2023 was CNY 1,515,723,471.89, representing a 67.9% increase from CNY 903,564,058.61 in Q1 2022[21] - The total comprehensive income for Q1 2023 was CNY 1,522,285,067.19, compared to CNY 896,950,266.96 in the same quarter last year[22] Cash Flow - The net cash flow from operating activities reached CNY 733,744,202.46, a remarkable improvement of 530.84% compared to a negative cash flow in the previous year[5] - Cash flow from operating activities generated a net amount of CNY 733,744,202.46, a significant recovery from a net outflow of CNY 170,306,941.45 in Q1 2022[23] - The net cash flow from investment activities was -315,633,657.92 CNY, compared to -816,681,896.54 CNY in the previous period[24] - The net cash flow from financing activities was 131,276,989.91 CNY, compared to 143,000,982.99 CNY in the previous period[24] - The total cash and cash equivalents at the end of the period amounted to 13,590,291,581.13 CNY, up from 13,046,160,012.47 CNY at the beginning of the period[24] - The net increase in cash and cash equivalents for the period was 544,131,568.66 CNY, compared to a decrease of 820,011,084.75 CNY in the previous period[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 54,732,796,774.46, up 2.65% from the end of the previous year[5] - The total liabilities decreased slightly to CNY 14,680,687,832.48 from CNY 14,793,946,606.95 in the previous year[19] - The total equity attributable to shareholders of the parent company increased to CNY 40,029,274,479.88 from CNY 38,503,673,731.86 year-on-year[19] Investment and Income - Investment income surged by 2,693.58% to CNY 242,399,008.29, primarily due to increased investment income from joint ventures[7] - The company reported a significant decrease in financial expenses by 75.03%, reflecting reduced interest income[7] - Research and development expenses increased to CNY 64,085,946.58, up 22.5% from CNY 52,322,884.63 in the previous year[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 184,251, with the top two shareholders holding a combined 49.27% of the shares[7] - The company plans to distribute a cash dividend of RMB 15.20 per 10 shares (including tax) to all shareholders[13] Corporate Developments - The company appointed Zhao Yingming as Chief Business Officer and Senior Vice President, effective immediately[12] - The company’s board of directors is in the process of electing a new chairman following the resignation of Wang Minghui[11] - The company plans to optimize its organizational structure in 2023 to enhance management capabilities and support strategic goals[15] - The company plans to continue its focus on R&D and market expansion in the pharmaceutical sector[11] Miscellaneous - The company did not undergo an audit for the first quarter report[25] - The company recognized credit impairment losses of 72,455.46 million yuan and asset impairment losses of 57,874.98 million yuan in 2022[14]